Institute of Anatomy and Cell Biology, Justus-Liebig-University Giessen, Giessen, Germany.
Department of Urology, Pediatric Urology, and Andrology, Justus-Liebig-University Giessen, Giessen, Germany.
FASEB J. 2018 Mar;32(3):1130-1138. doi: 10.1096/fj.201700430R. Epub 2018 Jan 3.
Prostate carcinoma and benign prostate hyperplasia (BPH) with associated lower urinary tract symptoms (LUTS) are among the most prevalent and clinically relevant diseases in men. BPH is characterized by an enlargement of prostate tissue associated with increased tone of smooth muscle cells (SMCs) which surround the single glands composing the prostate. Secretions of the glands leave the prostate through local excretory ducts during the emission phase of ejaculation. Pharmacological treatment of BPH suggests different local drug targets based on reduction of prostate smooth muscle tone as the main effect and disturbed ejaculation as a common side effect. This highlights the need for detailed investigation of single prostate glands and ducts. We combined structural and functional imaging techniques-notably, clear lipid-exchanged, acrylamide-hybridized rigid imaging/immunostaining/ in situ hybridization-compatible tissue-hydrogel (CLARITY) and time-lapse imaging-and defined glands and ducts as distinct SMC compartments in human and rat prostate tissue. The single glands of the prostate (comprising the secretory part) are characterized by spontaneous contractions mediated by the surrounding SMCs, whereas the ducts (excretory part) are quiescent. In both SMC compartments, phosphodiesterase (PDE)-5 is expressed. PDE5 inhibitors have recently emerged as alternative treatment options for BPH. We directly visualized that the PDE5 inhibitors sildenafil and tadalafil act by reducing spontaneous contractility of the glands, thereby reducing the muscle tone of the organ. In contrast, the ductal (excretory) system and thus the prostate's contribution to ejaculation is unaffected by PDE5 inhibitors. Our differentiated imaging approach reveals new details about prostate function and local drug actions and thus may support clinical management of BPH.-Kügler, R., Mietens, A., Seidensticker, M., Tasch, S., Wagenlehner, F. M., Kaschtanow, A., Tjahjono, Y., Tomczyk, C. U., Beyer, D., Risbridger, G. P., Exintaris, B., Ellem, S. J., Middendorff, R. Novel imaging of the prostate reveals spontaneous gland contraction and excretory duct quiescence together with different drug effects.
前列腺癌和良性前列腺增生症(BPH)伴有下尿路症状(LUTS)是男性中最常见和最相关的疾病。BPH 的特征是前列腺组织的增大,伴随着包围组成前列腺的单个腺体的平滑肌细胞(SMCs)的张力增加。腺体的分泌物在射精的排放阶段通过局部排泄管离开前列腺。BPH 的药物治疗建议根据减少前列腺平滑肌张力作为主要作用和干扰射精作为常见副作用的不同局部药物靶点。这突出表明需要详细研究单个前列腺腺体和导管。我们结合了结构和功能成像技术,特别是清晰的脂质交换、丙烯酰胺杂交刚性成像/免疫染色/原位杂交兼容组织水凝胶(CLARITY)和延时成像,并将人前列腺组织中的腺体和导管定义为不同的 SMC 隔室。前列腺的单个腺体(包含分泌部分)的特征是由周围 SMC 介导的自发收缩,而导管(排泄部分)是静止的。在这两个 SMC 隔室中,都表达磷酸二酯酶(PDE)-5。最近,PDE5 抑制剂已成为 BPH 的替代治疗选择。我们直接观察到 PDE5 抑制剂西地那非和他达拉非通过减少腺体的自发性收缩来发挥作用,从而降低器官的肌肉张力。相比之下,导管(排泄)系统,因此,前列腺对射精的贡献不受 PDE5 抑制剂的影响。我们的差异化成像方法揭示了前列腺功能和局部药物作用的新细节,因此可能支持 BPH 的临床管理。-Kügler,R.,Mietens,A.,Seidensticker,M.,Tasch,S.,Wagenlehner,F. M.,Kaschtanow,A.,Tjahjono,Y.,Tomczyk,C. U.,Beyer,D.,Risbridger,G. P.,Exintaris,B.,Ellem,S. J.,Middendorff,R. 前列腺的新型成像揭示了自发的腺体收缩和排泄管静止,以及不同的药物作用。